# Are peptides legal under the new HHS compounding policy?

Published November 13, 2026 · Updated November 13, 2026 · Data as of October 30, 2026

On October 30, 2026, HHS published a draft policy of enforcement discretion for licensed pharmacies and physicians that compound certain peptides. [1] Its Appendix A names [BPC-157](https://pepbank.io/p/bpc-157), Epitalon, KPV, MOTS-c, Semax and TB-500. [2] HHS says compounded drugs are not FDA-approved. HHS also calls the policy interim and not binding. [1] PepBank's records hold publications with findings in people for BPC-157, Epitalon and Semax, and none for KPV, MOTS-c or TB-500. [3, 4, 5, 6, 7, 8]

## Key points

- HHS says enforcement discretion is appropriate for BPC-157 acetate in subcutaneous, intramuscular, oral and topical dosage forms. [2]
- HHS says compounded drugs are not FDA-approved. [1, 2]
- The peptides are not yet on the 503A bulks list. FDA's future rulemakings may propose adding some or all of them. [1]
- PepBank's records hold no result from a study in people for KPV. [6]
- PepBank's regulatory record lists Semax as approved in Russia only, registered as Семакс. [9]

## What did HHS announce on October 30, 2026?

On October 30, 2026, HHS announced a draft Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. The notice appeared in the Federal Register. [1] HHS says it does not intend to pursue enforcement action against State-licensed pharmacies, Federal facilities or licensed physicians compounding with Appendix A peptides. [1, 2]

- [BPC-157](https://pepbank.io/p/bpc-157): HHS says enforcement discretion is appropriate for subcutaneous, intramuscular, oral and topical dosage forms of BPC-157 acetate. [2]
- [KPV](https://pepbank.io/p/kpv): HHS says enforcement discretion is appropriate for topical and oral dosage forms of KPV acetate. [2]
- [Semax](https://pepbank.io/p/semax): HHS says enforcement discretion is appropriate for intranasal use of semax free base. [2]
- Epitalon, MOTS-c and TB-500 are also named in Appendix A. [2]

HHS opened a comment period on Docket No. HHS-OASH-2026-0496. It runs until 2 weeks after publication in the Federal Register. [1]

Curo, a peptide shop with the same owner as PepBank, has a related article. [BPC-157 vs TB-500: Differences, and When Researchers Combine Them](https://curo.you/insights/bpc-157-vs-tb-500-differences-and-when-to-combine)

## Does the policy make these peptides FDA-approved?

HHS says compounded drugs are not FDA-approved. [1, 2] HHS calls the policy interim and says it may be revisited. HHS also says it creates no rights and is not binding. [1]

The peptides are not yet on the 503A bulks list, which is being developed through rulemaking. FDA's future rulemakings may propose adding some or all of them. [1] HHS may revisit the interim policy if a safety signal or product quality issue arises. [2]

BPC-157 and BPC-157 acetate were in Category 2 from September 2023 until April 22, 2026. HHS says neither the placement nor the removal changed their status under section 503A. [2] HHS says the same for TB-500, which was in Category 2 from September 29, 2023, until April 22, 2026. [2]

## What do PepBank's records hold for each peptide?

Peptides in Appendix A in PepBank's records, as of October 30, 2026

| Peptide | Studies with results | Publications with findings in people | Publications with findings in animals | Registered trials |
| --- | --- | --- | --- | --- |
| [BPC-157](https://pepbank.io/p/bpc-157) | 162 | 3 | 151 | 3 [2, 3] |
| [Epitalon](https://pepbank.io/p/epitalon) | 89 | 2 | 54 | 0 [2, 4] |
| [KPV](https://pepbank.io/p/kpv) | 28 | 0 | 16 | 0 [2, 6] |
| [MOTS-c](https://pepbank.io/p/mots-c) | 98 | 0 | 75 | 1 [2, 7] |
| [Semax](https://pepbank.io/p/semax) | 130 | 12 | 99 | 0 [2, 5] |
| [TB-500](https://pepbank.io/p/tb-500) | 7 | 0 | 6 | 1 [2, 8] |

PepBank's regulatory record lists BPC-157, Epitalon, KPV, MOTS-c and TB-500 as not approved for any use. [10, 11, 12, 13, 14] PepBank's regulatory record lists Semax as approved in Russia only, registered as Семакс. [9]

## Which of these peptides have studies in people?

In a small trial in people, 10 of 12 women with interstitial cystitis reported complete resolution of symptoms after one [BPC-157](https://pepbank.io/p/bpc-157) treatment. [15] In a knee pain study in patients, 11 of 12 who received only intra-articular BPC 157 (91.6%) reported significant improvement. [16] In a pilot study in people, intravenous BPC-157 infusions in 2 adults had no measurable effect on the tested heart biomarkers. [17]

PepBank holds 2 publications with findings in people for [Epitalon](https://pepbank.io/p/epitalon). [4] In patients with degenerative retinal lesions, Epitalon therapy gave a positive clinical effect in 90% of the cases. [18]

PepBank holds 12 publications with findings in people for [Semax](https://pepbank.io/p/semax). [5] In patients with acute hemispheric ischemic stroke, adding Semax to combined intensive therapy increased the regress of general cerebral disorders compared with conventional therapy. [19] In patients with motor neuron disease, 1% semax did not influence the course of chronic partial denervation. [20]

| Kind | Dose | Species | Route | Design | Source |
| --- | --- | --- | --- | --- | --- |
| Studied dose | 10 mg total | people | injection around the inflamed bladder area during cystoscopy | non-randomized trial | [15] |
| Studied dose | 12 mg daily | people | intranasal | non-randomized trial | [20] |

## What do the records hold for KPV, MOTS-c and TB-500?

PepBank's records hold no result from a study in people for KPV. [6] In mice, oral [KPV](https://pepbank.io/p/kpv) reduced the incidence of dextran sodium sulfate-induced colitis. [21]

PepBank's records hold no result from a study in people for MOTS-c. A trial registry lists 1 trial of MOTS-c in people. [7] In mice, [MOTS-c](https://pepbank.io/p/mots-c) treatment prevented age-dependent insulin resistance. [22]

PepBank's records hold no result from a study in people for TB-500. A trial registry lists 1 trial of TB-500 in people. [8] In rats with repaired Achilles tendons, [TB-500](https://pepbank.io/p/tb-500) increased maximum load to failure compared with controls. [23]

The [TB-500 studies](https://pepbank.io/p/tb-500/studies) in PepBank's records include 6 publications with findings in animals. [8] In two horses given TB-500 subcutaneously, N-acetylated LKKTETQ and its metabolite N-acetylated LK were detected in plasma. [24]

## FAQ

### Can a pharmacy compound BPC-157 now?

HHS says it does not intend to pursue enforcement action against State-licensed pharmacies, Federal facilities or licensed physicians compounding with Appendix A peptides. BPC-157 is named in Appendix A. [2] HHS says enforcement discretion is appropriate for subcutaneous, intramuscular, oral and topical dosage forms of BPC-157 acetate. [2] HHS says compounded drugs are not FDA-approved. [2]

### Is Semax approved anywhere?

PepBank's regulatory record lists Semax as approved in Russia only, registered as Семакс. [9] The Russian registration is a prescription medicine in nasal drops, held by Peptogen. Its listed 1% indication is the acute period of moderate to severe ischemic stroke, as part of combined therapy. [9] In the United States, HHS says enforcement discretion is appropriate for intranasal use of semax free base. [2]

### When does the comment period on the peptide policy end?

HHS opened a comment period on Docket No. HHS-OASH-2026-0496 on regulations.gov. HHS says it lasts until 2 weeks after the date of publication in the Federal Register. [1] HHS announced the draft policy on October 30, 2026. [1] HHS calls the policy interim and says it may be revisited. [1]

### Has MOTS-c been tested in people?

PepBank's records hold no result from a study in people for MOTS-c. A trial registry lists 1 trial of MOTS-c in people. [7] PepBank holds 75 publications with findings in animals and 53 with laboratory findings in cells or tissue for MOTS-c. [7] In mice of 2, 12 and 22 months, MOTS-c significantly enhanced physical performance. [25]

## Sources

1. Federal Register, Volume 91 Issue 209 (Friday, October 30, 2026). Federal Register, 2026-10-30. https://www.federalregister.gov/documents/full_text/text/2026/10/30/2026-22192.txt
2. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. U.S. Department of Health and Human Services, 2026-10-30. https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf
3. BPC-157 in PepBank. PepBank, 2026-10-30. https://pepbank.io/p/bpc-157
4. Epitalon in PepBank. PepBank, 2026-10-30. https://pepbank.io/p/epitalon
5. Semax in PepBank. PepBank, 2026-10-30. https://pepbank.io/p/semax
6. KPV in PepBank. PepBank, 2026-10-30. https://pepbank.io/p/kpv
7. MOTS-c in PepBank. PepBank, 2026-10-30. https://pepbank.io/p/mots-c
8. TB-500 in PepBank. PepBank, 2026-10-30. https://pepbank.io/p/tb-500
9. Semax: regulatory status in PepBank. PepBank, 2026-10-30. https://pepbank.io/p/semax
10. BPC-157: regulatory status in PepBank. PepBank, 2026-10-30. https://pepbank.io/p/bpc-157
11. Epitalon: regulatory status in PepBank. PepBank, 2026-10-30. https://pepbank.io/p/epitalon
12. KPV: regulatory status in PepBank. PepBank, 2026-10-30. https://pepbank.io/p/kpv
13. MOTS-c: regulatory status in PepBank. PepBank, 2026-10-30. https://pepbank.io/p/mots-c
14. TB-500: regulatory status in PepBank. PepBank, 2026-10-30. https://pepbank.io/p/tb-500
15. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Alternative therapies in health and medicine, 2024-10-01. https://pubmed.ncbi.nlm.nih.gov/39325560/ PMID 39325560. Evidence class: human.
16. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Alternative therapies in health and medicine, 2021-07-01. https://pubmed.ncbi.nlm.nih.gov/34324435/ PMID 34324435. Evidence class: human.
17. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Alternative therapies in health and medicine, 2025-09-01. https://pubmed.ncbi.nlm.nih.gov/40131143/ PMID 40131143. Evidence class: human.
18. Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa. Neuro endocrinology letters, 2002-08-01. https://pubmed.ncbi.nlm.nih.gov/12195242/ PMID 12195242. Evidence class: human.
19. [Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study)]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 1997-01-01. https://pubmed.ncbi.nlm.nih.gov/11517472/ PMID 11517472. Evidence class: human.
20. [The study of chronic partial denervation and quality of life in patients with motor neuron disease treated with semax]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2007-01-01. https://pubmed.ncbi.nlm.nih.gov/18379501/ PMID 18379501. Evidence class: human.
21. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology, 2007-10-17. https://pubmed.ncbi.nlm.nih.gov/18061177/ PMID 18061177. Evidence class: animal.
22. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell metabolism, 2015-03-01. https://pubmed.ncbi.nlm.nih.gov/25738459/ PMID 25738459. Evidence class: animal.
23. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Joint diseases and related surgery, 2026-07-23. https://pubmed.ncbi.nlm.nih.gov/42542926/ PMID 42542926. Evidence class: animal.
24. Doping control analysis of seven bioactive peptides in horse plasma by liquid chromatography-mass spectrometry. Analytical and bioanalytical chemistry, 2013-01-15. https://pubmed.ncbi.nlm.nih.gov/23318763/ PMID 23318763. Evidence class: animal.
25. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature communications, 2021-01-20. https://pubmed.ncbi.nlm.nih.gov/33473109/ PMID 33473109. Evidence class: animal.

How this article is made: PepBank writes its articles from the studies and records in its database. Each claim links to its source. [Read how PepBank collects and classes evidence.](https://pepbank.io/methods)

Canonical: https://pepbank.io/blog/are-peptides-legal-hhs-compounding-policy

This is not medical advice.
